1285513-35-0 Usage
Benzamide derivative
A compound derived from benzoic acid and an amine, containing a benzene ring and an amide functional group.
Benzyl group
A phenyl group (a six-membered aromatic ring with a single hydrogen atom) attached to a methylene group (-CH2-).
Methyl group
A chemical group consisting of one carbon atom bonded to three hydrogen atoms (-CH3).
Pyridin-3-yl group
A pyridine derivative with a substituent attached to the third carbon atom of the six-membered nitrogen-containing aromatic ring.
Potential drug candidate
A chemical compound that shows promise for therapeutic applications and is being studied for its pharmacological properties.
Pharmacological properties
Characteristics of a compound that determine its potential for therapeutic use, such as its ability to interact with biological systems and affect physiological processes.
Biological systems
The complex, interconnected systems within living organisms that govern their functions and processes.
Physiological processes
The various functions and activities that occur within living organisms, such as metabolism, growth, and immune response.
Further research
Additional studies and investigations needed to fully understand the properties, potential uses, and safety of a chemical compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1285513-35-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,5,5,1 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1285513-35:
(9*1)+(8*2)+(7*8)+(6*5)+(5*5)+(4*1)+(3*3)+(2*3)+(1*5)=160
160 % 10 = 0
So 1285513-35-0 is a valid CAS Registry Number.
1285513-35-0Relevant academic research and scientific papers
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Ding, Xiao,Dai, Xuedong,Long, Kai,Peng, Cheng,Andreotti, Daniele,Bamborough, Paul,Eatherton, Andrew J.,Edge, Colin,Jandu, Karamjit S.,Nichols, Paula L.,Philps, Oliver J.,Stasi, Luigi Piero,Wan, Zehong,Xiang, Jia-Ning,Dong, Kelly,Dossang, Pamela,Ho, Ming-Hsun,Li, Yi,Mensah, Lucy,Guan, Xiaoming,Reith, Alastair D.,Ren, Feng
, p. 4034 - 4038 (2017/08/23)
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.
NOVEL COMPOUNDS
-
, (2011/04/25)
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
